Autism spectrum disorders (ASD) have a prevalence of up to 2.7% and show significant rates of comorbidities. Pharmacological treatment can be difficult. New treatment options are needed, several are currently under investigation. Publication bias presents a major problem in current clinical research. This study was designed to quantify publication bias in rigorously designed ASD research. The database at ClinicalTrials.gov was searched for all completed research. Yet, clinical research and medicine in general is highly specialized today. In order to address the problem of publication bias, professionals need to be provided with figures relating to their fields of research or medical practice. The current publication bias in ASD is uncertain. Due to this lack of transparency, the practice of evidencebased medicine in ASD can be distorted. We therefore directed our efforts to the quantification of publication bias in ASD research.
. Over the last decade, ASD have been an entity of particular interest and the number of recognized diagnoses has risen worldwide. ASD show a prevalence of up to 2.7% depending on the population investigated (Brugha et al., 2011; Kim et al., 2011) . Recent data from the United States report the prevalence of ASD to be one out of every 68 children, or 14.7 per 1,000 (Centres for Disease Control and Prevention, 2014 ). Yet, these rates are discussed critically in the literature (Mandell & Lecavalier, 2014) . Depending on the classification methodology they may differ and, specifically, be lower when strictly applying the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria (Smith, Reichow, & Volkmar, 2015) .
ASD have an early onset before the age of three years and are lifelong conditions with significant rates of comorbidities, e.g. major depression, attention deficit/hyperactivity disorder, anxiety disorders (Hofvander et al., 2009) . In spite of extensive research, the etiology of ASD is still unknown (Ghosh, Michalon, Lindemann, Fontoura, & Santarelli, 2013) . Treatment of ASD can be difficult, and the disease can be severely disabling thus resulting in multiple challenges for patients and afflicted families. Current pharmacological treatment strategies show comparably high rates of adverse events (especially for antipsychotic compounds) which can be a significant burden to patients and their families, and, thus, potentially lower medication adherence (Posey, Stigler, Erickson, & McDougle, 2008) . New treatment options are needed which provide both clinical efficacy and tolerability/safety (Hampson, Gholizadeh, & Pacey, 2012; Maglione, Gans, Das, Timbie, & Kasari, 2012) . From another perspective, this need also represents opportunities for researchers and pharmaceutical companies to develop and profit from new treatment approaches (Ghosh et al., 2013 (Easterbrook, Gopalan, Berlin, & Matthews, 1991; Hart, Lundh, & Bero, 2012; Dwan, Gamble, Williamson, & Kirkham, 2013; Wager & Williams, 2013) .
Recently, 13,327 completed clinical trials registered at ClinicalTrials.gov from a five-year-period were evaluated for publication bias. Of these, 13.4% of trials reported results within 12 months after completion while 38.3% of trials reported results at any time after completion (Anderson et al., 2015) . This estimates the publication bias for the investigated five-year-period at approximately 60%. Anderson et al. (2015) comprehensively analysed all clinical trials regardless of the field of research, disease or drug investigated, and thus presented an overview of publication bias in current clinical research. Yet, clinical research and medicine in general is highly specialized today. In order to address the problem of publication bias, professionals need to be provided with figures relating to their fields of research or medical practice. The current publication bias in ASD is uncertain. Due to this lack of transparency, the practice of evidencebased medicine in ASD can be distorted. We therefore directed our efforts to the quantification of publication bias in ASD research.
| METHODS

| Database search
From all clinical trials registered there, the database at http://www. clinicaltrials.gov was searched for completed randomized controlled clinical trials investigating therapeutic interventions in ASD. We focussed on randomized-controlled (double blind) interventional clinical trials because they potentially represent the most robust level of evidence. Keywords used for the database search on ClinicalTrials.
gov were: "double blind", "placebo-controlled study", "randomized", "efficacy", "completed", "autism", and "child". Data were downloaded on 22 January 2015 and manually checked independently by two authors for plausibility. To assess the status of publication of these trials' results, the respective entry of the database at http://www. clinicaltrials.gov was searched for results made public there or references/links to publications reporting results from the trial. If no results and no references were provided at the ClinicalTrials.gov database, a thorough search of the scientific databases of the US National Library of Medicine NIH (PubMed) at http://www.ncbi.nlm.nih.gov/pubmed (PubMed) and Google Scholar at http://www.scholar.google.com was performed using the ClinicalTrials.gov identification number (NCT), the intervention investigated, keywords, sponsor information, details of the study design and "autism" as search terms. If no publications could be found by these means, an enquiry was sent to the responsible parties and/or sponsors listed at the trial's respective entry at the ClinicalTrials.gov database via e-mail.
| Definition of publication bias
If no publications could be retrieved through the database search described earlier and by direct enquiry of the responsible party or sponsor, results from a clinical trial were defined as not published.
On the contrary, reports of trial results were defined as published if any peer-reviewed manuscript published by a scientific journal could be identified. Results provided at http://www.clinicaltrials.gov were also considered peer-reviewed since all entries are reviewed by an expert prior to being made publicly accessible. Research conference abstracts and press releases were not considered peer-reviewed and consequently these trials' results were defined as not published.
| Statistical analysis
The ratio as a percentage between published and unpublished results according to the definition used in this study represented the estimation of the publication bias for clinical trials in ASD. Trial characteristics were described by methods of standard descriptive statistics. Time to publication was computed as the time of publication minus the time of trial completion. All analyses were performed using SAS software (SAS Institute, Cary, NC, USA). The p-values reported were two-sided. 
| Trial characteristics
Years of completion of clinical trials ranged from 2001 to 2014, i.e. the observation period of this study covers the last 14 years. Table 1 summarizes key characteristics of the identified 50 interventional trials. Eighty-six per cent of trials included paediatric populations exclusively, and 78% of trials investigated drugs. Thirty-eight per cent were Phase 2 while 24% were Phase 3 trials. Funding was provided by industry for 42%, by the NIH and/or US Federal Funding for 20% of trials. Forty-two per cent of trials were indicated as having received funding from other sources. Yet, the term "other" was not defined any further in the ClinicalTrials.gov database.
| Quantification of publication bias
Thirty trials (60%) were published and 20 trials (40%) were not published as defined by publication in a peer-reviewed manuscript. The majority of trials investigated drugs but also dietary, behavioural, biological interventions, medical devices and procedures were studied. Drug development is a costly and time consuming process (Ciociola, Cohen, & Kulkarni, 2014) . Recruiting paediatric patients with psychiatric disorders into interventional trials is particularly challenging (Bliznak, Berg, Häge, & Dittmann, 2013) .
The largest of the unpublished randomized controlled clinical trials investigated drugs that have been granted marketing approvals for treatment of other disorders, e.g. memantine in Alzheimer's disease (480 patients), fluoxetine and sertraline in major depressive disorder (266 patients), and lurasidone (150 patients) in schizophrenia (cf. This has also been shown for evidence of early intensive behavioural and developmental interventions in ASD (Warren et al., 2011) . In 2012, a number of experts emphasized the existing research gap for evidence of efficacy of non-pharmacological treatments of ASD (Maglione et al., 2012) . The results presented in this study, despite focussing on randomized controlled trials, further underline this issue.
A recently published analysis of clinical trials in general used a very similar methodology as provided here, and reported comparable rates (Huser & Cimino, 2013) .
In anxiety disorders, reporting biases have been analysed and found to lead to significant increases in the number of positive findings in the literature compared to reviews by the US Food and Drug Administration (FDA) (Roest et al., 2015) . Pharmaceutical companies may In this study, responsible parties or sponsors of the respective clinical trials were contacted if no publications could be found by the methods described. Although extensive efforts were made to identify current contact information, it is possible that contact information may have been outdated or incomplete. From some contacted individuals or companies no response was received. Reasons for this remain unknown. The results presented here for research in ASD will serve as reference data for future studies reassessing publication bias and tracking potential progress resulting from recent and future advances and intentions to minimize publication bias.
